Correction
Oncology
Amila Suraweera, Alex Duff, Mark N. Adams, Christian Jekimovs, Pascal H. G. Duijf, Cheng Liu, Matthew McTaggart, Sam Beard, Kenneth J. O'Byrne, Derek J. Richard
Summary: A correction to the paper has been published.
BRITISH JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Mohammad Mojtaba Sadeghi, Mohamed F. Salama, Yusuf A. Hannun
Summary: Driver-directed therapeutics have significantly improved cancer treatment efficacy and quality of life, but resistance acquisition remains a major challenge in targeted therapy for NSCLC. PKC isoforms have been implicated as mediators of drug resistance in NSCLC, with upregulation correlating with worse prognosis. Predictive biomarkers for PKC activity are needed for better results in clinical trials, and tandem inhibition of PKC and molecular drivers may offer a potential therapeutic strategy to prevent resistance emergence.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemical Research Methods
Boyu Pan, Chen Huang, Yafei Xia, Cuicui Zhang, Bole Li, Liangjiao Wang, Senbiao Fang, Liren Liu, Shu Yan
Summary: In this study, hub targets associated with non-small cell lung cancer (NSCLC) were identified using multiple databases. The gene COL1A1 was found to be a potential prognostic marker and therapeutic target for NSCLC.
CURRENT BIOINFORMATICS
(2022)
Article
Biochemistry & Molecular Biology
Hao Cheng, Shi-Jiang Wang, Zhi Li, Yan Ma, Yang-Rong Song
Summary: A study found that downregulation of ING2 is associated with poor prognosis in non-small-cell lung carcinoma (NSCLC). Experimental results showed that ING2 can inhibit the growth, infiltration, metastasis, and promote apoptosis of NSCLC cells, possibly through the epithelial-mesenchymal transition (EMT) process. Further research revealed that ING2 silencing suppressed the expression of Wilms tumor 1-associated protein (WTAP), and overexpression of WTAP partially counteracted the effect of ING2 silencing on cell proliferation. In addition, elevated levels of WTAP were correlated with poor prognosis in NSCLC.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Biochemical Research Methods
Yimin Luo, Xihua Wang, Li Li, Qun Wang, Yue Hu, Can He, Mei Zhang
Summary: This study revealed that the centromere protein family members were dysregulated and correlated with poor prognosis in LUAD patients, with CENPK showing the strongest correlation with NSCLC patients' prognosis. High expression of CENPK was significantly correlated with shorter OS and DFS in different stage NSCLC patients. Additionally, CENPK was found to be significantly correlated with lymphocytes and immunomodulators using the TISIDB database, indicating its potential as a novel biomarker for NSCLC diagnosis.
CURRENT BIOINFORMATICS
(2021)
Article
Immunology
Binbin Zhang, Aiqun Xu, Dong Wu, Wanli Xia, Pulin Li, Enze Wang, Rui Han, Peng Sun, Sijing Zhou, Ran Wang
Summary: The study revealed that ARL14 expression was higher in NSCLC patients compared to normal tissues, and it was significantly correlated with poor survival, indicating its potential as a prognostic biomarker for NSCLC.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Oncology
Htoo Zarni Oo, Zoltan Lohinai, Nastaran Khazamipour, Joey Lo, Gunjan Kumar, Jessica Pihl, Hans Adomat, Noushin Nabavi, Hakhamanesh Behmanesh, Beibei Zhai, Robert Dagil, Swati Choudhary, Tobias Gustavsson, Thomas M. Clausen, Jeffrey D. Esko, Jeffrey W. Allen, Michael A. Thompson, Nhan L. Tran, Judit Moldvay, Balazs Dome, Ali Salanti, Nader Al-Nakouzi, Glen J. Weiss, Mads Daugaard
Summary: Targeting oncofetal chondroitin sulfate (CS) chains can serve as a prognostic and therapeutic strategy for non-small cell lung cancer (NSCLC), with high expression associated with poorer outcomes. Both clinical and preclinical studies demonstrate the potential of oncofetal CS as a actionable prognostic marker and therapeutic target in NSCLC.
Review
Cell Biology
Jason Hongting Leung, Benjamin Ng, Wei-Wen Lim
Summary: This article reviews the role of interleukin-11 (IL11) as a potential biomarker in non-small cell lung cancer (NSCLC). It identifies the need for biomarkers in NSCLC and summarizes the available information. Accumulating evidence suggests IL11 to be a potential biomarker in NSCLC patients, but further research is needed.
Article
Multidisciplinary Sciences
Rui Guo, Xiaoyu Gong, Kongzhao Li, Zhengqi Qiu, Lina Yang, Yanbin Wan, Xinhuang Yao, Canling Long, Jiqing Xu, Kang Li, Jingyan Liu, Jia Liu
Summary: This study identified xanthine oxidase (XO) as a potential target of realgar against non-small cell lung cancer (NSCLC) through network pharmacology and experimental validation. XO was upregulated in NSCLC tumor tissue and correlated with poor overall survival. Molecular docking and experimental validation revealed a possible interaction between realgar and XO. Realgar treatment suppressed XO activity in NSCLC cells, and the mechanism of action in the cell-cell junction organization pathway was investigated.
Article
Oncology
Feyza Sen, Gabriel T. Sheikh, Johannes von Hinten, Andreas Schindele, Malte Kircher, Alexander Dierks, Christian H. Pfob, Sebastian E. Serfling, Andreas K. Buck, Theo Pelzer, Takahiro Higuchi, Alexander Weich, Ralph A. Bundschuh, Rudolf A. Werner, Constantin Lapa
Summary: Despite the availability of novel targeted treatment options, small cell lung cancer (SCLC) still has a poor prognosis. This study aimed to evaluate the prognostic value of somatostatin receptor (SSTR) expression assessed by positron emission tomography (PET) and investigate the efficacy of SSTR-targeted radionuclide therapy (PRRT). The results showed that SSTR-targeted PET is not a prognostic tool for outcome in SCLC patients, but it can be an important tool for treatment decision. PRRT may be a promising treatment option for some patients with SCLC as a second or third line treatment.
Article
Biochemistry & Molecular Biology
William C. C. Cho, Chi F. F. Wong, Kwan P. P. Li, Alvin H. H. Fong, King Y. Y. Fung, Joseph S. S. Au
Summary: Our previous study showed that miR-145 is downregulated in NSCLC tissues and inhibits cell proliferation. In this study, we found that miR-145 is also downregulated in NSCLC plasma samples and is associated with NSCLC in patients. Additionally, we discovered that transfection of miR-145 inhibits the proliferation, migration, and invasion of NSCLC cells and delays tumor growth in a mouse model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Piaoyang Liu, Shun Li, Liling Tang
Summary: NGF plays a crucial role in the occurrence and development of various lung diseases by changing protein expression levels and mediating cell function. Anti-NGF may be used in future therapeutic strategies for lung diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, Jonas Kuon, Daniel Kazdal, Hannah Schindler, Rajiv Shah, Anna-Lena Volckmar, Fabienne Lusky, Leonore Diekmann, Stephan Liersch, Martin Faehling, Thomas Muley, Mark Kriegsmann, Karolina Benesova, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Summary: A study on NSCLC patients receiving PD-(L)1 inhibitors in a German academic center found that approximately one-fourth of patients develop immune-related adverse events (irAEs), most of which require treatment suspension and steroid therapy. The occurrence of irAEs is associated with PD-L1 positive tumors, lower neutrophil-to-lymphocyte ratios, and better ECOG performance status, but independently linked to longer survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lu Peng, Yihao Tao, Rui Wu, Jing Su, Maoyuan Sun, Yuan Cheng, Zongyi Xie, Jinning Mao, Xiaohui Zhan, Guodong Liu
Summary: This study identified NFATc1 and NFATc3 as potentially important regulators in the occurrence of NSCLC and BM by targeting IL-11, CDH5, and CCL2.
FRONTIERS IN ONCOLOGY
(2021)
Review
Health Care Sciences & Services
Michal Szczyrek, Paulina Bitkowska, Marta Jutrzenka, Janusz Milanowski
Summary: Lung cancer, a leading cause of global cancer-related deaths, is often diagnosed at advanced stages due to limited diagnostic possibilities. However, the use of miRNAs as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC) has gained attention in recent years. Abnormal expression levels of miRNAs can detect NSCLC in its early asymptomatic stages, potentially improving clinical outcomes and serving as predictive factors for NSCLC treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
Fraser J. Brims, Annette McWilliams, Susan V. Harden, Ken O'Byrne
MEDICAL JOURNAL OF AUSTRALIA
(2022)
Article
Immunology
Habib Sadeghirad, James Monkman, Ahmed M. Mehdi, Rahul Ladwa, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe
Summary: By applying targeted spatial proteomic approaches, this study investigated the protein expression in primary and lymph node metastases and found that lymph node metastases had higher levels of proliferation, DNA repair, and apoptosis markers, while pro-apoptotic markers were enriched in the stroma of primary tumors. This study highlights the utility of spatial proteomics for understanding the tumor and stromal composition in locoregional metastasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Kar Ven Cavan Chow, Connor O'Leary, Fiona Paxton-Hall, Duncan Lambie, Kenneth O'Byrne
Summary: This case report describes a 63-year-old man with metastatic lung adenocarcinoma who developed toxic epidermal necrolysis (TEN) following treatment with pembrolizumab. The patient was managed with immunosuppressive therapy and achieved excellent recovery. This rare occurrence highlights the importance of recognizing and managing this complication, especially considering the increasing use of immune checkpoint inhibitors.
OXFORD MEDICAL CASE REPORTS
(2022)
Article
Oncology
Malinda Itchins, Hannah Ainsworth, Marliese Alexander, Samantha Dean, Devi Dharmaraj, Nick Pavlakis, Stephen J. Clarke, Chris Brown, Javier Torres, Ayesha Saqib, Rahul Ladwa, Kenneth O'Byrne, Melissa Moore, Po Yee Yip, Ben Ben Solomon, Tom John, Steven Kao, Paul Mitchell, Sagun Parakh
Summary: Limited real world data exist on the IMpower150 regimen, and this study adds to the knowledge base by demonstrating its efficacy in EGFR mutant patients, including those with CNS metastases. The overall response rate for all patients was 51%, and for EGFR mutant patients it was 52%, highlighting the positive outcomes of this treatment approach.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Joanna Kapeleris, Juliana Muller Bark, Shanon Ranjit, Derek Richard, Ian Vela, Kenneth O'Byrne, Chamindie Punyadeera
Summary: This study found that hypoxic conditions enhance the proliferation and clonogenicity of non-small cell lung cancer cell lines. Additionally, cells exposed to hypoxia and reoxygenation showed altered expression of epithelial-mesenchymal transition-related genes at both mRNA and protein levels. Therefore, considering the epithelial-mesenchymal transition status is essential for a comprehensive understanding of circulating tumor cells in NSCLC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Immunology
Arutha Kulasinghe, Ning Liu, Chin Wee Tan, James Monkman, Jane E. Sinclair, Dharmesh D. Bhuva, David Godbolt, Liuliu Pan, Andy Nam, Habib Sadeghirad, Kei Sato, Gianluigi Li Bassi, Ken O'Byrne, Camila Hartmann, Anna Flavia Ribeiro Dos Santos Miggiolaro, Gustavo Lenci Marques, Lidia Zytynski Moura, Derek Richard, Mark Adams, Lucia de Noronha, Cristina Pellegrino Baena, Jacky Y. Suen, Rakesh Arora, Gabrielle T. Belz, Kirsty R. Short, Melissa J. Davis, Fernando Souza-Fonseca Guimaraes, John F. Fraser
Summary: The study reveals distinct transcriptomic profiles in cardiac tissues of SARS-CoV-2 and pH1N1 influenza infection, with upregulation of genes associated with DNA damage and repair, heat shock, and macrophage infiltration in COVID-19 patients' cardiac tissues. In comparison, pH1N1 infection showed upregulation of interferon and complement pathways. This highlights the need for further understanding of the effects on extra-pulmonary organs, including the cardiovascular system, in COVID-19 patients.
Article
Biochemistry & Molecular Biology
Tabassum Khair Barbhuiya, Mark Fisher, Eric D. Boittier, Emma Bolderson, Kenneth J. O'Byrne, Derek J. Richard, Mark Nathaniel Adams, Neha S. Gandhi
Summary: The study investigates the mechanism of CDCA3 binding to APC/C-Cdh1 through the non-canonical ABBA-like motif. The research finds that H-bonds, hydrophobic and ionic interactions within the ABBA-like motif are crucial for the binding. Alanine mutations disrupt the structure of the linker region, leading to altered affinities and binding to alternate sites on Cdh1.
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Mark N. Adams, Laura V. Croft, Aaron Urquhart, Mohamed Ashick Mohamed Saleem, Anja Rockstroh, Pascal H. G. Duijf, Patrick B. Thomas, Genevieve P. Ferguson, Idris Mohd Najib, Esha T. T. Shah, Emma Bolderson, Shivashankar Nagaraj, Elizabeth D. Williams, Colleen C. Nelson, Kenneth J. O'Byrne, Derek J. Richard
Summary: This study evaluated the role of hSSB1/NABP2 in modulating the cellular response to androgens and ionizing radiation in prostate cancer. The expression of hSSB1 in prostate cancer is correlated with genomic instability and it regulates pathways involved in cell cycle progression and transcription. Additionally, hSSB1 is involved in modulating androgen response through transcriptional regulation. Exploiting hSSB1 in prostate cancer treatment might improve patient outcomes in ADT and/or radiotherapy.
Review
Oncology
Eabha O'Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy Gately
Summary: KRAS plays a crucial role in regulating cell growth and survival, and its activation is commonly observed in various types of tumors. Recent discoveries have identified a specific pocket in the structure of KRAS, leading to the development of inhibitors that target the G12C mutation. These inhibitors, such as sotorasib and adagrasib, have been approved for the treatment of non-small-cell lung cancer, but their efficacy may be limited by resistance mechanisms in cancer cells.
Article
Oncology
Ming Tang, Joshua T. Burgess, Mark Fisher, Didier Boucher, Emma Bolderson, Neha S. Gandhi, Kenneth J. O'Byrne, Derek J. Richard, Amila Suraweera
Summary: This study aimed to explore the binding pose of COMMD4-H2B and develop a H2B peptide that disrupts the COMMD4-H2B interaction, which could serve as a potential therapeutic target for non-small cell lung cancer (NSCLC).
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Sugandha Bhatia, Jennifer H. Gunter, Joshua Burgess, Mark N. Adams, Kenneth O'Byrne, Erik W. Thompson, Pascal H. G. Duijf
Summary: Epithelial-mesenchymal plasticity (EMP) is a characteristic of cancer that promotes invasion, metastasis, and therapy resistance. This study shows that non-cancerous human epithelial lung cells can spontaneously shift towards a mesenchymal-like state without genetic changes. This suggests that acquisition of metastasis-associated features may occur prior to genetic alterations and cancerous transformation.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Biology
Zachariah P. Schuurs, Alexander P. Martyn, Carl P. Soltau, Sam Beard, Esha T. Shah, Mark N. Adams, Laura V. Croft, Kenneth J. O'Byrne, Derek J. Richard, Neha S. Gandhi
Summary: This study explores small molecules that bind to hSSB1, an important protein related to the survival of cancer cells. Through computational and experimental approaches, three small molecules were discovered that prevent hSSB1 from binding to DNA, potentially interfering with the cell's ability to repair DNA. Further research is needed to understand the interaction between these compounds and cells, and to develop them as selective hSSB1 inhibitors.
Article
Chemistry, Physical
Ming Tang, Amila Suraweera, Xuqiang Nie, Zilin Li, Pinglin Lai, James W. Wells, Kenneth J. O'Byrne, Robert J. Woods, Emma Bolderson, Derek J. Richard
Summary: In this study, the atomic-level mechanisms of Banf1-DNA binding and the effects of mono- and di-phosphorylation on Banf1's DNA-binding capability were explored using molecular modelling and dynamics simulations. It was found that mono-phosphorylation induces changes in Banf1's secondary structure, leading to the elimination of its DNA-binding capability. The study also demonstrated that phosphorylated Banf1 binds to DNA with lower affinity and less stable binding poses. These findings have implications for predicting the effects of Banf1 mutations on its DNA-binding capability and potential development of therapeutic drugs targeting cell proliferation.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS
(2023)
Article
Multidisciplinary Sciences
Thais Sobanski, Amila Suraweera, Joshua T. Burgess, Iain Richard, Chee Man Cheong, Keyur Dave, Maddison Rose, Mark N. Adams, Kenneth J. O'Byrne, Derek J. Richard, Emma Bolderson
Summary: This study reveals that the glycolytic protein ALDOA plays a direct role in DNA double-strand break (DSB) repair. Upon DNA damage, ALDOA translocates into the nucleus and associates with the DNA DSB marker γ-H2AX. Depletion of ALDOA leads to increased DNA damage before and slower repair after ionising radiation. It is suggested that targeting ALDOA may be a potential strategy for simultaneous disruption of cancer metabolism and DNA repair.
SCIENTIFIC REPORTS
(2023)